Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant pertuzumab plus trastuzumab and chemotherapy in operable HER2-positive breast cancer
NL-OMON55519Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Chemotherapy + trastuzumab + pertuzumab with Chemotherapy + trastuzumab + placebo (2 arms). Primary endpoint: Invasive disease-free survival. Started Jun 2012; status: completed.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON55519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55519.